These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 16380836)

  • 41. Pemetrexed and its emerging role in the treatment of thoracic malignancies.
    Scagliotti GV; Novello S
    Expert Opin Investig Drugs; 2003 May; 12(5):853-63. PubMed ID: 12720495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M; White RM; Johnson JR; Pazdur R
    Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An assessment of the antithymine and antipurine characteristics of MTA (LY231514) in CCRF-CEM cells.
    Chen VJ; Bewley JR; Smith PG; Andis SL; Schultz RM; Iversen PW; Tonkinson JL; Shih C
    Adv Enzyme Regul; 2000; 40():143-54. PubMed ID: 10828350
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
    Solomon B; Bunn PA
    Future Oncol; 2005 Dec; 1(6):733-46. PubMed ID: 16556051
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.
    Desmoulin SK; Hou Z; Gangjee A; Matherly LH
    Cancer Biol Ther; 2012 Dec; 13(14):1355-73. PubMed ID: 22954694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging role of pemetrexed in ovarian cancer.
    Tomao F; Panici PB; Frati L; Tomao S
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
    Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pemetrexed in patients with gastrointestinal carcinoma.
    de Gramont A; Kindler HL
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):42-9. PubMed ID: 12023792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma.
    Chen JS; Chao Y; Bang YJ; Roca E; Chung HC; Palazzo F; Kim YH; Myrand SP; Mullaney BP; Shen LJ; Linn C
    Anticancer Drugs; 2010 Sep; 21(8):777-84. PubMed ID: 20634689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells.
    Yang TY; Chang GC; Hsu SL; Huang YR; Chiu LY; Sheu GT
    Biomed Res Int; 2013; 2013():389046. PubMed ID: 23984356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.
    Izbicka E; Diaz A; Streeper R; Wick M; Campos D; Steffen R; Saunders M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):993-9. PubMed ID: 19221750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
    Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
    Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
    Wang Y; Zhao R; Goldman ID
    Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
    Fizazi K; John WJ; Vogelzang NJ
    Semin Oncol; 2002 Feb; 29(1):77-81. PubMed ID: 11836672
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.
    Simon GR; Manegold C; Barker SS; Treat JA; Visseren-Grul C; Obasaju C
    Clin Lung Cancer; 2013 Nov; 14(6):601-8. PubMed ID: 23921171
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pemetrexed safety and dosing strategy.
    Niyikiza C; Hanauske AR; Rusthoven JJ; Calvert AH; Allen R; Paoletti P; Bunn PA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):24-9. PubMed ID: 12571807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular, biochemical, and cellular pharmacology of pemetrexed.
    Goldman ID; Zhao R
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
    Calvert H
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.